Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
National Energy Services Reunited Corp - Warrants
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Incyclix Bio
Incyclix Bio Establishes Steering Committee of Leading Breast Cancer Experts to Guide INX-315 Clinical Development
Today 8:00 EST
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
December 17, 2025
From
Incyclix Bio
Via
GlobeNewswire
Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025
September 22, 2025
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
August 25, 2025
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer
April 29, 2025
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Announces Publication in Nature Communications Highlighting Biomarkers of Response to CDK2 Inhibition
February 13, 2025
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
December 13, 2024
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
November 18, 2024
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Expands Board of Directors with Appointment of Norman E. Sharpless, MD
November 12, 2024
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Announces Abstract Accepted for Presentation at 2024 San Antonio Breast Cancer Symposium
November 04, 2024
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
August 20, 2024
From
Incyclix Bio
Via
GlobeNewswire
Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
February 28, 2023
From
Incyclix Bio
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
